<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment of adult patients with Brugada syndrome</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment of adult patients with Brugada syndrome</h1>
<div class="graphic"><div class="figure"><div class="ttl">Treatment of adult patients with Brugada syndrome</div><div class="cntnt"><img src="data:png;base64,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"/></div><div class="graphic_footnotes"><p>ECG: electrocardiogram; ICD: implantable cardioverter-defibrillator; VT: ventricular tachycardia; NSAID: nonsteroidal anti-inflammatory drug.</p>
<p>* Acetaminophen preferred; NSAID may be added if needed in absence of risk factors for NSAID toxicity.</p>
<p>¶ Refer to UpToDate content for further information. Full list of drugs to be avoided is available at <a href="https://www.brugadadrugs.org/" target="_blank">https://www.brugadadrugs.org/</a>.</p>
<p>Δ High-risk features include sudden cardiac arrest, arrhythmogenic syncope, documented sustained VT, and family history of Brugada syndrome.</p>
<p>◊ Refer to UpToDate content for further information regarding patients who are good candidates for ICDs.</p>
<p>§ Quinidine oral dose is 1 to 1.5 g/day of quinidine sulfate or 600 to 900 mg/day of hydroquinidine (not available in the United States), typically divided into three to four equal daily doses. Small studies have suggested that lower doses of quinidine sulfate (300 to 600 mg/day) may be effective in some patients. Strength of quinidine products available outside the United States may be expressed as salt or quinidine base; refer to local labeling for equivalence before use.</p>
<p>¥ Amiodarone oral dose is 200 mg daily after an initial oral loading dose (typically 400 mg twice daily or 200 mg three times daily for one to two weeks).</p>
‡ Significant burden of sustained ventricular tachycardia.</div><div id="graphicVersion">Graphic 141883 Version 2.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
